XNK Therapeutics targets broader pipeline opportunities for its NK cell therapy
September 29, 2021 XNK Therapeutics AB (“XNK”) today announced plans to further expand the scope of its proprietary technology platform of natural killer (NK) cell therapies outside of multiple myeloma to also include other cancer indications to broaden the pipeline. The company will begin the preclinical and commercial work to expand the pipeline and expects to announce a decision in Q1 2022.XNK is at the forefront of the clinical development and manufacturing of autologous natural killer cell-based products by using its proprietary technology platform. XNK has promising clinical data